We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Urine Test Diagnoses Early-Stage Prostate Cancer

By LabMedica International staff writers
Posted on 01 May 2025
Print article
Image: Prostate cancer can be diagnosed at an early stage through a simple urine sample (Photo courtesy of Shutterstock)
Image: Prostate cancer can be diagnosed at an early stage through a simple urine sample (Photo courtesy of Shutterstock)

Prostate cancer is one of the leading causes of death among men worldwide. A major challenge in diagnosing the disease is the absence of reliable biomarkers that can detect early-stage tumors. Now, a study published in Cancer Research reveals that prostate cancer can be diagnosed at an early stage using a simple urine sample.

Researchers from Karolinska Institutet (Stockholm, Sweden), utilizing artificial intelligence (AI) and comprehensive analyses of gene activity in prostate tumors, have discovered new biomarkers with high diagnostic accuracy. By analyzing the mRNA activity of all human genes in thousands of individual cells within prostate tumors, and considering the location and degree of cancer in each cell, the researchers were able to develop digital models of prostate cancer. These models were then analyzed with AI to identify proteins that could serve as biomarkers. The identified biomarkers were subsequently tested in the blood, prostate tissue, and urine of nearly 2,000 patients.

The team discovered a set of biomarkers in urine that could accurately indicate both the presence and severity of prostate cancer. According to their findings, these biomarkers outperform PSA, the blood biomarker currently used in clinical practice. The next phase of research involves large-scale clinical trials to further validate these results. More precise biomarkers than PSA could lead to earlier detection and better prognoses for men with prostate cancer. Additionally, they could help reduce the number of unnecessary prostate biopsies in healthy men.

“There are many advantages to measuring biomarkers in urine,” explains principal investigator Mikael Benson, senior researcher at the Department of Clinical Science, Intervention and Technology, Karolinska Institutet. “It’s non-invasive and painless and can potentially be done at home. The sample can then be analyzed using routine methods in clinical labs.”

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
New
PSA Test
Humasis PSA Card

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.